BG107370A - Novel interferon for treatment of multiple sclerosis - Google Patents

Novel interferon for treatment of multiple sclerosis

Info

Publication number
BG107370A
BG107370A BG107370A BG10737002A BG107370A BG 107370 A BG107370 A BG 107370A BG 107370 A BG107370 A BG 107370A BG 10737002 A BG10737002 A BG 10737002A BG 107370 A BG107370 A BG 107370A
Authority
BG
Bulgaria
Prior art keywords
multiple sclerosis
treatment
beta2
inf
interferon
Prior art date
Application number
BG107370A
Other languages
Bulgarian (bg)
English (en)
Inventor
Edward CROZE
Daryl Faulds
Charis WAGNER
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of BG107370A publication Critical patent/BG107370A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BG107370A 2000-06-16 2002-12-11 Novel interferon for treatment of multiple sclerosis BG107370A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21204600P 2000-06-16 2000-06-16
US09/881,050 US20020025304A1 (en) 2000-06-16 2001-06-15 Novel interferon for the treatment of multiple sclerosis
PCT/US2001/041022 WO2001095929A2 (en) 2000-06-16 2001-06-18 Interferon for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
BG107370A true BG107370A (en) 2003-11-28

Family

ID=26906704

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107370A BG107370A (en) 2000-06-16 2002-12-11 Novel interferon for treatment of multiple sclerosis

Country Status (22)

Country Link
US (1) US20020025304A1 (xx)
EP (1) EP1289541A2 (xx)
JP (1) JP2004505021A (xx)
KR (1) KR20030009529A (xx)
CN (1) CN1436086A (xx)
AU (1) AU2001267099A1 (xx)
BG (1) BG107370A (xx)
BR (1) BR0111852A (xx)
CA (1) CA2413077A1 (xx)
CZ (1) CZ20024094A3 (xx)
EE (1) EE200200693A (xx)
HU (1) HUP0300787A2 (xx)
IL (1) IL152996A0 (xx)
LT (1) LT2002123A (xx)
MX (1) MXPA02012308A (xx)
NO (1) NO20025964L (xx)
NZ (1) NZ522849A (xx)
PL (1) PL359562A1 (xx)
RU (1) RU2003100517A (xx)
SI (1) SI21080A (xx)
SK (1) SK17612002A3 (xx)
WO (1) WO2001095929A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2004046365A2 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1712992A1 (en) * 2005-04-11 2006-10-18 Sony Ericsson Mobile Communications AB Updating of data instructions
EP2536435B1 (en) * 2010-02-18 2017-11-15 Janssen Biotech, Inc. Monkey homolog of human interferon omega
WO2017134306A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Cd8 binding agents
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
PL317197A1 (en) * 1994-05-10 1997-03-17 Immulogic Pharma Corp Compositions for and method of treating sclerosis multiplex
AU761577C (en) * 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
CN1299285A (zh) * 1998-05-29 2001-06-13 拜奥根有限公司 重组人干扰素β－1A(IFN－β－1A)制剂
WO2000017361A2 (en) * 1998-09-18 2000-03-30 Zymogenetics, Inc. Interferon-epsilon
WO2001079289A2 (en) * 2000-04-14 2001-10-25 Zymogenetics, Inc. Human interferon, zinf2

Also Published As

Publication number Publication date
EE200200693A (et) 2004-06-15
NZ522849A (en) 2004-05-28
MXPA02012308A (es) 2003-04-25
EP1289541A2 (en) 2003-03-12
JP2004505021A (ja) 2004-02-19
SK17612002A3 (sk) 2003-08-05
KR20030009529A (ko) 2003-01-29
US20020025304A1 (en) 2002-02-28
RU2003100517A (ru) 2004-06-27
WO2001095929A2 (en) 2001-12-20
NO20025964D0 (no) 2002-12-12
NO20025964L (no) 2003-02-14
CZ20024094A3 (cs) 2003-05-14
IL152996A0 (en) 2003-06-24
HUP0300787A2 (hu) 2003-07-28
BR0111852A (pt) 2003-05-20
CN1436086A (zh) 2003-08-13
CA2413077A1 (en) 2001-12-20
AU2001267099A1 (en) 2001-12-24
LT2002123A (en) 2003-06-25
SI21080A (sl) 2003-06-30
PL359562A1 (en) 2004-08-23
WO2001095929A3 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
EP1033998A4 (en) METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER
NZ248377A (en) Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
DE69914463D1 (en) Therapeutische chemokine rezeptor antagonisten
ATE406176T1 (de) Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
EP0457195A3 (en) Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
PL370070A1 (en) Vaccine and method for treatment of motor neurone diseases
BG107370A (en) Novel interferon for treatment of multiple sclerosis
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
GB0127983D0 (en) Treatment of micro-organism infection
DE50010519D1 (de) Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
IL145722A0 (en) Pharmaceutical composition comprising growth hormone and interferon
RU2004104335A (ru) Биологически активные пептиды
WO2004074312A3 (en) Tryptophyllin peptides and uses thereof
UA66749C2 (en) Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
WO2000026362A3 (de) Proteine der stomatinfamilie und ihre verwendung als zielproteine für die schmerztherapie
AU7435298A (en) Compositions for enhancing immunosuppressants' pharmaceutical acti vities
NZ336371A (en) Human gene therapy using DNA/RNA cassette expression systems